Results 241 to 250 of about 154,826 (359)

Stem cells for the heart, are we there yet? [PDF]

, 2003
De Sutter, Johan, Gillebert, Thierry, Timmermans, Frank   +2 more
core   +2 more sources

Revaccinatio in children following autologous and allogeneic hematopoietic stem cell transplantation in an oncohematology reference center in Brazil

, 2016
Fernanda Aparecida Vargas de Brito e Alves
openalex   +1 more source

Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma

, 2012
Neil Dunavin, Lai Wei, Patrick Elder, Gary Phillips, Don M. Benson, Craig C. Hofmeister, Sam Penza, Carli N Greenfield, Karen Rose, Gisele Rieser, Lisa Merritt, Jill Ketcham, Nyla A. Heerema, John C. Byrd, Steven M. Devine, Yvonne A. Efebera   +15 more
openalex   +2 more sources

Filgrastim after autologous stem cell transplantation shortens time to neutrophil recovery and hospital stay. [PDF]

Ann Hematol
Oosterink KA, Dekker TJA, Tjon JML, Marijt WAF, Te Boome LCJ, Veelken H, von dem Borne PA, Halkes CJM.   +7 more
europepmc   +1 more source

A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL‐321

British Journal of Haematology, EarlyView.
Summary BRUIN CLL‐321 is the first prospective, randomized study conducted in covalent BTK inhibitor (cBTKi) pretreated chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) patients. In this heavily pretreated population, pirtobrutinib significantly improved progression‐free survival (PFS) compared to investigator's choice (IC) of ...
Shuhua Yi, Jiang Cao, Ru Feng, Keshu Zhou, Lihua Qiu, Fei Li, Hai Yan Yang, Hui Zhou, Wuhan Hui, Jie Cui, He Huang, Jiankun Zhu, Xiuhui Ye, Jeff Sharman, Lugui Qiu   +14 more
wiley   +1 more source

Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years

, 2016
Arne Kolstad, Lone Bredo Pedersen, Christian Winther Eskelund, Simon Husby, Kirsten Grønbæk, Mats Jerkeman, Anna Laurell, Riikka Räty, Erkki Elonen, Niels Smedegaard Andersen, Peter de Nully Brown, Eva Kimby, Hans Bentzen, Christer Sundström, Mats Ehinger, Marja‐Liisa Karjalainen‐Lindsberg, Jan Delabie, Elisabeth Ralfkiær, Unn‐Merete Fagerli, Herman Nilsson‐Ehle, Grete F. Lauritzsen, Outi Kuittinen, Carsten Utoft Niemann, Christian H. Geisler   +23 more
openalex   +1 more source

Sporadic late-onset nemaline myopathy with cardiomyopathy presenting as advanced heart failure despite autologous stem cell transplantation: a case report. [PDF]

Eur Heart J Case Rep
Guo C, Dou JH, Zhao S, Zhang Y.
europepmc   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Pharmacoeconomic Analysis of Palifermin to Prevent Mucositis among Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation

, 2014
Ajay K. Nooka, H. R. M. Johnson, Jonathan L. Kaufman, Christopher R. Flowers, Amelia Langston, Conor E. Steuer, Michael Graiser, Zahir Ali, Nishi Shah, Sravanti Rangaraju, Dana Nickleach, Jingjing Gao, Sagar Lonial, Edmund K. Waller   +13 more
openalex   +1 more source

Monovalent mannose‐glycoconjugates of sulforaphane reprogram human dendritic cells via NFATc1 to induce immune tolerance under inflammatory conditions

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Immune tolerance prevents inflammation and autoimmunity, with dendritic cells (DCs) playing a key role. Reprogramming DCs towards a tolerogenic state represents a promising therapeutic strategy. Sulforaphane (SFN) has known immunomodulatory effects, but its clinical application is limited by poor stability and ...
María Elena Angarita‐Planchez, Camila Leiva‐Castro, Ana M. Múnera‐Rodríguez, Macarena Martínez‐Bailén, Ana T. Carmona, Soledad López‐Enríquez, Francisca Palomares   +6 more
wiley   +1 more source